In April 2013 the UK Government rolled out new legislation enabling companies to opt into a scheme in order to apply a lower rate of tax …
Over the last few years there has been a shift in conducting clinical trials away from North America and Europe and towards emerging markets, particularly …
Training on its own tends to work quite well when people need to make a small change to the way they work. Also, some mandatory training, …
Mobile devices are now a major part of all our lives. Michael Whitworth at Quanticate looks into how this could quite easily, in controlled way, be delivered …
Clinical site workflow and processes can have an enormous impact on the quality of data generated in a clinical trial. All too often, however, important factors like …
High-priced prescription drugs have been making headlines for years, but soaring insurance premiums have put drug costs back in the spotlight. Ryan Mcguire, Rochelle gagg …
The need to improve and accelerate the success of drug development in schizophrenia has resulted in the increased utilisation of novel pharmacodynamic methodologies that may readily translate …
Igor Stefanov at Synergy Research Group looks into clinical trials in Russia in Q1 2013, which were sponsored by companies from 20 countries. The highest number of …
Asia nowadays is considered definitively as the fastest-growing market, and a consolidated area for drug development. Asia not only offers the highest number of treatment-naïve patients able …
Clinical research is very well organised in Saudi Arabia, with many centres/sites conducting local and multi-centric trials. Big pharmaceutical companies are now looking at Saudi Arabia …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
